Unspecified Childhood Solid Tumor, Protocol Specific
Conditions
Brief summary
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Phase I trial to study the effectiveness of bortezomib in treating children who have advanced solid tumors that have not responded to previous treatment.
Detailed description
PRIMARY OBJECTIVES: I. Determine the maximum tolerated dose of bortezomib in pediatric patients with refractory solid tumors. II. Determine the dose-limiting toxicity and other toxic effects of this regimen in these patients. III. Preliminarily determine the antitumor activity of this regimen in these patients. OUTLINE: This is a dose-escalation study. Patients receive bortezomib IV on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of bortezomib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. If dose-limiting toxicity in the form of myelosuppression occurs in stratum I, dose escalation continues with patients meeting the qualifications for stratum II. PROJECTED ACCRUAL: Approximately 24-36 patients will be accrued for this study.
Interventions
DRUGbortezomib
Given IV
OTHERlaboratory biomarker analysis
Correlative studies
OTHERpharmacological study
Correlative studies
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 21 Years
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed solid tumor that is refractory to standard therapy or for which no standard therapy exists * Histologic confirmation not required for brainstem glioma or optic pathway tumor * Ineligible for therapies of higher priority * Stratum II only: * No bone marrow involvement * Performance status - Karnofsky 50-100% (over 10 years of age) * Performance status - Lansky 50-100% (10 years of age and under) * At least 8 weeks * Absolute neutrophil count at least 1,500/mm\^3 * Platelet count at least 75,000/mm\^3 (transfusion independent) * Hemoglobin at least 8 g/dL (RBC transfusions allowed) * Bilirubin less than 1.5 mg/dL * ALT less than 5 times normal for age * Albumin at least 2 g/dL * Creatinine no greater than upper limit of normal for age * Creatinine clearance or radioisotope glomerular filtration rate greater than 70 mL/min * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Neurologic deficits related to CNS tumors allowed if relatively stable for at least 2 weeks * No uncontrolled infection * At least 7 days since prior biologic therapy and recovered * At least 3 months since prior allogeneic stem cell transplantation * At least 1 week since prior growth factors * Stratum II only: * No prior stem cell transplantation with or without total body irradiation * At least 2 weeks since prior chemotherapy (4 weeks for nitrosoureas) and recovered * Stratum II only: * No more than 2 prior multi-agent chemotherapy regimens * More than 2 single-agent regimens allowed * Concurrent dexamethasone allowed for CNS tumors if stable dose for at least 2 weeks * See Biologic therapy * At least 2 weeks since prior palliative local radiotherapy * At least 6 months since prior craniospinal radiotherapy or radiotherapy to at least 50% of pelvis * At least 6 weeks since prior substantial bone marrow radiotherapy * Recovered from prior radiotherapy * Stratum II only: * No prior radiotherapy to more than 20% of bone marrow * No prior bortezomib * No concurrent anticonvulsants * No other concurrent investigational agents
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival | Up to 24 months | — |
| MTD defined as the dose at which fewer than 20% of patients experience DLT assessed using CTC version 2.0 | 3 weeks | — |
| 20S proteasome inhibition | Up to 2 weeks | The 95% confidence interval for the percent of patients who exhibit inhibition at a recommended dose level determined according to the table above is 61%-100%, if six patients are evaluated or 55%-100% if five patients are evaluated. |
Countries
United States
Outcome results
None listed